DE60304726T2 - Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer - Google Patents

Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer Download PDF

Info

Publication number
DE60304726T2
DE60304726T2 DE60304726T DE60304726T DE60304726T2 DE 60304726 T2 DE60304726 T2 DE 60304726T2 DE 60304726 T DE60304726 T DE 60304726T DE 60304726 T DE60304726 T DE 60304726T DE 60304726 T2 DE60304726 T2 DE 60304726T2
Authority
DE
Germany
Prior art keywords
sulfonyl
mixture
methoxy
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304726T
Other languages
German (de)
English (en)
Other versions
DE60304726D1 (de
Inventor
Michael E. Newport Beach Garst
George Encino Sachs
Jai Moo Northridge Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Winston Pharmaceuticals LLC
US Department of Veterans Affairs
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
Winston Pharmaceuticals LLC
US Department of Veterans Affairs
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Winston Pharmaceuticals LLC, US Department of Veterans Affairs, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Application granted granted Critical
Publication of DE60304726D1 publication Critical patent/DE60304726D1/de
Publication of DE60304726T2 publication Critical patent/DE60304726T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE60304726T 2002-07-19 2003-07-15 Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer Expired - Lifetime DE60304726T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39745902P 2002-07-19 2002-07-19
US397459P 2002-07-19
PCT/US2003/022419 WO2004009583A2 (en) 2002-07-19 2003-07-15 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor

Publications (2)

Publication Number Publication Date
DE60304726D1 DE60304726D1 (de) 2006-05-24
DE60304726T2 true DE60304726T2 (de) 2007-08-09

Family

ID=30771064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60304726T Expired - Lifetime DE60304726T2 (de) 2002-07-19 2003-07-15 Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer

Country Status (22)

Country Link
US (3) US6897227B2 (enExample)
EP (1) EP1556371B1 (enExample)
JP (1) JP4463103B2 (enExample)
KR (2) KR100822981B1 (enExample)
AT (1) ATE323695T1 (enExample)
AU (1) AU2003259154B2 (enExample)
BR (1) BR0312802A (enExample)
CA (1) CA2492718C (enExample)
CO (1) CO5690576A2 (enExample)
DE (1) DE60304726T2 (enExample)
DK (1) DK1556371T3 (enExample)
ES (1) ES2263028T3 (enExample)
IL (1) IL166371A0 (enExample)
MX (1) MXPA05000657A (enExample)
NO (1) NO20050801L (enExample)
NZ (1) NZ538221A (enExample)
PL (1) PL375255A1 (enExample)
PT (1) PT1556371E (enExample)
RU (1) RU2292342C2 (enExample)
TW (1) TW200502231A (enExample)
WO (1) WO2004009583A2 (enExample)
ZA (1) ZA200501116B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
EP1644352A1 (en) * 2003-07-15 2006-04-12 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
CA2557471A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
EP1715861A2 (en) * 2004-02-18 2006-11-02 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
BRPI0507796A (pt) * 2004-03-11 2007-07-17 Allergan Inc métodos e composições para o tratamento de condições relacionadas com a secreção de ácido gástrico
ATE437869T1 (de) 2004-04-28 2009-08-15 Hetero Drugs Ltd Verfahren zur herstellung von pyridinylmethyl-1h- benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
WO2007081871A1 (en) * 2006-01-10 2007-07-19 Allergan, Inc. Therapeutic salt compositions of sulfonyl ester prodrugs of proton pump inhibitors and methods for their preparation
BRPI0711048A2 (pt) * 2006-05-09 2011-08-23 Astrazeneca Ab formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
EP2193518A4 (en) * 2007-10-05 2010-10-27 Lg Electronics Inc PLASMA DISPLAY DEVICE
KR20090035195A (ko) * 2007-10-05 2009-04-09 엘지전자 주식회사 플라즈마 디스플레이 장치
KR100895333B1 (ko) * 2007-11-01 2009-05-07 엘지전자 주식회사 플라즈마 디스플레이 패널의 구동 방법 및 그를 이용한플라즈마 디스플레이 장치
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2012087872A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
KR20130133219A (ko) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Crth₂ 수용체 조절제로서의 퀴녹살린 및 아자-퀴녹살린
EP3242664A4 (en) * 2015-01-09 2018-06-20 The Regents of the University of California Compositions and methods for treating gastrointestinal infections
CN108997177A (zh) * 2018-09-04 2018-12-14 邵阳学院 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US430042A (en) * 1890-06-10 Valve
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
US4758597A (en) * 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5045522A (en) * 1990-03-27 1991-09-03 Phillips Petroleum Company Absorption composition comprising zinc titanate for removal of hydrogen sulfide from fluid streams
PL166209B1 (pl) * 1990-06-20 1995-04-28 Astra Ab Sposób wytwarzania nowych pochodnych benzimidazolu PL
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
NZ288609A (en) * 1994-06-10 1998-12-23 Byk Gulden Lomberg Chem Fab Substituted (4-thiopyridinyl) methylthio-benzimidazole (or 1h-imidazo-[2,3-b]-pyridine) and medicaments
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CN100396675C (zh) * 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
EP1535921A1 (en) * 1998-08-12 2005-06-01 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6599167B2 (en) * 2000-09-27 2003-07-29 Glenn Waltz Game call holder and amplifying device
US20040039027A1 (en) 2000-10-12 2004-02-26 Keiji Kamiyama Benzimidazole compounds, process for producing the same and use thereof

Also Published As

Publication number Publication date
JP2005536519A (ja) 2005-12-02
AU2003259154B2 (en) 2006-12-07
US20040102484A1 (en) 2004-05-27
WO2004009583A3 (en) 2004-03-18
ATE323695T1 (de) 2006-05-15
NO20050801L (no) 2005-02-15
WO2004009583A2 (en) 2004-01-29
RU2005105564A (ru) 2005-10-10
KR100788778B1 (ko) 2007-12-27
US20050182101A1 (en) 2005-08-18
DE60304726D1 (de) 2006-05-24
DK1556371T3 (da) 2006-08-21
NZ538221A (en) 2006-11-30
JP4463103B2 (ja) 2010-05-12
US6897227B2 (en) 2005-05-24
ES2263028T3 (es) 2006-12-01
AU2003259154A1 (en) 2004-02-09
US20050143423A1 (en) 2005-06-30
KR20050047078A (ko) 2005-05-19
RU2292342C2 (ru) 2007-01-27
ZA200501116B (en) 2006-11-29
KR20070005029A (ko) 2007-01-09
HK1079207A1 (en) 2006-03-31
MXPA05000657A (es) 2005-08-19
TW200502231A (en) 2005-01-16
EP1556371B1 (en) 2006-04-19
PL375255A1 (en) 2005-11-28
IL166371A0 (en) 2006-01-16
CA2492718A1 (en) 2004-01-29
AU2003259154C1 (en) 2004-02-09
CA2492718C (en) 2010-12-21
EP1556371A2 (en) 2005-07-27
CO5690576A2 (es) 2006-10-31
BR0312802A (pt) 2005-04-19
KR100822981B1 (ko) 2008-04-16
PT1556371E (pt) 2006-09-29

Similar Documents

Publication Publication Date Title
DE60304726T2 (de) Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
DE69905171T2 (de) Prodrugs für proton-pump-inhibitoren
EP0201575B1 (de) Neue picolinderivate, verfahren zu ihrer herstellung, ihre anwendung und sie enthaltende arzneimittel
DE3789536T2 (de) Pyridin-Derivate, deren pharmazeutische Zusammenstellungen, deren Anwendung für die Herstellung von Arzneimitteln mit therapeutischem oder vorbeugendem Wert und Verfahren zu deren Herstellung.
EP0149088B1 (de) Neue Pyridin-2-ether beziehungsweise Pyridin-2-thioether mit einem stickstoffhaltigen cycloaliphatischen Ring sowie deren Sulforide, Sulfone und Pyridin-N-oxide
DE69722027T2 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
DE2548340C2 (enExample)
DE69914854T2 (de) Sulfoxidderivate und Acetonkomplexe und Verfahren zu ihrer Herstellung
EP0001279A1 (de) Imidazolderivate deren Herstellung und diese enthaltende Präparate
DE3404610A1 (de) Benzimidazolderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
EP2060569A1 (de) 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat-Hemihydrat und dessen Verwendung als Arzneimittel
DD142882A5 (de) Verfahren zur herstellung von pyridylmethylsulfinylbenzimidazolen
DD252375A5 (de) Verfahren zur herstellung von benzimidazolderivaten
EP1891046A1 (de) Polymorphe von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE3216843A1 (de) Thiomethylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3781703T2 (de) 2-benzimidazolylalkylthio(oder sulfinyl- oder sulfonyl)-derivate, verfahren zu deren herstellung und deren anwendung als arzneimittel.
DE60312953T2 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
DE69722002T2 (de) Tricyclische n-cyanoimine als inhibitoren der farnesyl-protein transferase
AT392788B (de) Neue benzimidazolverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DD290192A5 (de) Pyridinderivat mit antiulzeroeser wirkung
DD210909A5 (de) Verfahren zur herstellung von substituierten 3,4-diamino-1,2,5-thiadiazolverbindungen
DE60009301T2 (de) Benzimidazolverbindungen
CH630907A5 (en) Process for preparing derivatives of 1-carbamoyluracil.
HK1079207B (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
DD270531A5 (de) Verfahren zur herstellung von benzimidazolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition